John Charles Thomas net worth and biography

John Thomas Biography and Net Worth

EVP, General Counsel & Corporate Secretary of Krystal Biotech

John Thomas is EVP, General Counsel & Corporate Secretary at Krystal. Before Krystal, he was a partner at the Webb Law Firm. John has represented pharmaceutical companies as well as other fortune 500 companies with regard to litigation and intellectual property matters. John was a founder and former managing partner of Beck & Thomas, P.C. He was named in Best Lawyers in America from 2016-2022 for Intellectual Property law (litigation) Pittsburgh, PA, 2017-2022 Patent Law and Trademark law, Pittsburgh, and was the Best Lawyers in America 2018 Trademark Lawyer of the Year–Pittsburgh PA. He holds a B.S. in Chemistry from Indiana University of Pennsylvania and a J.D. from Duquesne Law, Cum Laude. John was an Associate Recent Decisions Editor of the Duquesne Law Review.

What is John Charles Thomas' net worth?: The estimated net worth of John Charles Thomas is at least $363.44 thousand as of June 25th, 2026. Mr. Thomas owns 1,000 shares of Krystal Biotech stock worth more than $363,440 as of July 13th. This net worth estimate does not reflect any other assets that Mr. Thomas may own. Learn More about John Charles Thomas' net worth.
How do I contact John Charles Thomas?: The corporate mailing address for Mr. Thomas and other Krystal Biotech executives is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. Krystal Biotech can also be reached via phone at (412) 586-5830 and via email at [email protected]. Learn More on John Charles Thomas' contact information.
Has John Charles Thomas been buying or selling shares of Krystal Biotech?: John Charles Thomas has not been actively trading shares of Krystal Biotech during the last quarter. Most recently, John Charles Thomas sold 1,000 shares of the business's stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $347.27, for a transaction totalling $347,270.00. Following the completion of the sale, the executive vice president now directly owns 1,000 shares of the company's stock, valued at $347,270. Learn More on John Charles Thomas' trading history.
Who are Krystal Biotech's active insiders?: Krystal Biotech's insider roster includes Julian Gangolli (Director), Daniel Janney (Director), Krish Krishnan (CEO), Suma Krishnan (COO), Kathryn Romano (CAO), Dino Rossi (Director), and John Thomas (EVP, General Counsel & Corporate Secretary). Learn More on Krystal Biotech's active insiders.
Are insiders buying or selling shares of Krystal Biotech?: In the last year, insiders at the sold shares 19 times. They sold a total of 216,679 shares worth more than $53,681,592.08. The most recent insider tranaction occured on June, 25th when EVP John Charles Thomas sold 1,000 shares worth more than $347,270.00. Insiders at Krystal Biotech own 13.1% of the company. Learn More about insider trades at Krystal Biotech.
Information on this page was last updated on 6/25/2026.

John Charles Thomas Insider Trading History at Krystal Biotech

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/25/2026	Sell	1,000	$347.27	$347,270.00	1,000
5/26/2026	Sell	642	$302.03	$193,903.26

John Charles Thomas Buying and Selling Activity at Krystal Biotech

Krystal Biotech Company Overview

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Today's Range

Now: $363.44

$353.49

$367.79

50 Day Range

MA: $327.17

$284.57

$378.15

2 Week Range

Now: $363.44

$130.50

$382.54

Volume

378,804 shs

Average Volume

306,798 shs

Market Capitalization

$10.71 billion

P/E Ratio

48.59

Dividend Yield

N/A

Beta

0.5